The Philadelphia drug injury lawyers at Feldman & Pinto are evaluating Onglyza drug injury cases from people injured by Onglyza side effects.
Onglyza is a type 2 diabetes drug made by Britol-Myers Squib. The FDA approved the drug for treatment of certain diabetes symptoms.
Onglyza use is linked to an increased risk of:
- pancreatic cancer, and
- thyroid cancer
- heart failure
- liver toxicity
- kidney injury
- renal failure
Onglyza drug injury lawsuits brought against Bristol-Myers Squib allege that the company:
- knew that Onglyza could cause pancreatic cancer and other serious injuries
- failed to warn doctors and consumers of the known risk of these side effects, and
- improperly marketed Onglyza despite knowledge of these dangers
The Philadelphia Medical Malpractice Attorneys at the law firm of Feldman & Pinto also hold doctors accountable for Onglyza injuries and deaths caused by their substandard care.
Doctors can be liable in medical negligence actions for patient injuries and deaths caused by:
- the negligent prescription of Onglyza to patients who are at increased risk of suffering dangerous Onglyza side effects, and /or
- the negligent failure to take reasonable action to prevent these side effects in patients who use Onglyza
Onglyza and Pancreatic Cancer
Onglyza is a dipeptidyl peptidase-4 (DPP-4) inhibitor / incretin therapy drug that aids in the reduction of high blood sugar following a meal. Onglyza is one of a class of drugs that may increase a patient’s risk of pancreatic cancer. Other incretin therapy drugs and incretin mimetics associated with an increase in pancreatic cancer risk include:
- Janumet (see Philadelphia Janumet Drug Injury Lawyers)
- Januvia (see Philadelphia Januvia Drug Injury Lawyers)
- Victoza (see Philadelphia Victoza Drug Injury Lawyers)
- Byetta (see Philadelphia Byetta Drug Injury Lawyers)
- Bydureon (see Philadelphia Bydureon Drug Injury Lawyers)
- Janumet XR
Pancreatic cancer is a deadly disease generally not diagnosed until the cancer is in its late stages. At the third and fourth stages, the cancer may have spread to a patient’s:
- lymph nodes
- bloodstream, and
- other organs
At least one study found that Onglyza doubled the risk of pancreatic cancer in users of the drug.
Onglyza and Heart Failure
In April 2016, the FDA issued an alert about the increased risk of heart failure in people who use Onglyza. The risk is even greater in people with a history of heart disease or kidney disease. The FDA is adding new warnings to the drug’s labels regarding these risks. Onglyza drug injury lawsuits filed against the drug’s maker seek damages for patients’ heart failure and other serious injuries caused by this dangerous drug.
Onglyza FDA Warnings and Studies
Incretin therapy drugs such as Onglyza were linked to an increased pancreatic cancer risk and a six-fold increase in pancreatitis in a study reported in the July 2011 issue of Gastroenterology. Drugs studied included DPP-4 inhibitors as well as glucagonlike peptide 1 (GLP-1) receptor agonists (incretin mimetics).
The U.S. Food and Drug Administration (FDA) issued a drug safety communication on March 14, 2013, regarding a possible increase in pancreatitis and pancreatic duct metaplasia risk in users of Onglyza and similar pharmaceuticals.
A study reported by the National Institutes of Health (NIH) on April 8, 2013, revealed a significant increase in risk of acute pancreatitis in users of DPP-4 inhibitor or glucagonlike peptide 1 (GLP-1) drugs. Study subjects who had used this incretin therapy had enlarged pancreases that were 40% above normal size.
Contact a Philadelphia Onglyza Drug Injury Lawyer
You may be entitled to money damages if you suffered personal injuries after use of Onglyza. Please contact us to learn more about filing an Onglyza drug injury lawsuit. Our personal injury lawyers can help you obtain the compensation and justice you deserve.